Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

Hepatology

Volumn 49, Issue 1, 2009, Pages 72-79

  Leung, Nancy ^a   Peng, Cheng Yuan ^b   Hann, Hie Won ^c   Sollano, Jose ^d   Lao Tan, Judy ^e   Hsu, Chao Wei ^f   Lesmana, Laurentius ^g   Yuen, Man Fung ^h   Jeffers, Lennox ⁱ   Sherman, Morris ^j   Min, Albert ^k   Mencarini, Kimberly ^l   Diva, Ulysses ^l   Cross, Anne ^l   Wilber, Richard ^l   Lopez Talavera, Juan ^l  

^a ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF SANTO TOMAS   (Philippines)

^e Cebu Doctors Hospital   (Philippines)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g UNIVERSITY OF INDONESIA   (Indonesia)

^h QUEEN MARY HOSPITAL   (Hong Kong)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j TORONTO GENERAL HOSPITAL   (Canada)

^k BETH ISRAEL MEDICAL CENTER   (United States)

^l BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; HEPATITIS B(E) ANTIGEN; PHOSPHONIC ACID DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; ADOLESCENT; BLOOD; GENETICS; HEPATITIS B VIRUS; MULTICENTER STUDY; VIROLOGY;

ADENINE; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; PHOSPHONIC ACIDS; VIRAL LOAD;

EID: 58949087420     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22658     Document Type: Article

References (31)

1. Hepatitis B fact sheet. Geneva: World Health Organization, October 2000. Available at http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed November 11, 2008.
2. Perrillo R. Hepatitis B virus replication x time equals trouble. Gastroenterology 2006;130:989-991.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
5. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
7. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
8. Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
10. Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005;42(Suppl):aBstr 36.
11. Tenney DJ, Pokorowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008;2(Suppl):aBstr PL04.
12. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354: 1001-1010.
13. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354: 1011-1020.
14. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al; AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudinere-fractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049.
15. Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: A randomized double-blind trial in China. Hepatology Int 2007;1:365-372.
16. Yao G, Zhou X, Xu D, Wang B, Ren H, Liu J, et al. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int 2007;1:373-381.
17. Gish R, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444.
18. Shouval D, Akarca US, Hatzis G, Kitis G, Lai CL, Cheinquer H, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027) [abstract 45]. J Hepatol 2006;44(Suppl 2):S21.
19. Yurdaydin C, Sollano J, Hadziyannis S, Kaymakoglu S, Sherman M, Brett-Smith H, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) [abstract 80]. J Hepatol 2006;44(Suppl 2):S36.
20. Han S, Chang T, Chao Y, Yoon S, Gish RG, Cheinquer H, et al. Four-year entecavir treatment in nucleoside-naïve HBeAg(+) patients: Results from studies ETV-022 and -901 [abstract 938]. HEPATOLOGY 2007;46(Suppl 1):654A.
21. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. HEPATOLOGY 1999;29:1863-1869.
22. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:4398-4402.
23. Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-144.
24. Leon LF, Cross A. Viral kinetic modeling of HBV DNA. Presented at the International Biometrics Society, Eastern North American Region Spring Meeting 2007, March 11-14, 2007. Abstract 98.
25. Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-Infected Chinese patients: A viral dynamics study. HEPATOLOGY 2000;32: 394-399.
26. Rice JA, Silverman BW. Estimating the mean and covariance structure nonparametrically when the data are curves. J R Stat Soc B 1991;53:233-243.
27. Neumann AU. Hepatitis B viral kinetics: A dynamic puzzle still to be resolved. HEPATOLOGY 2005;42:249-254.
28. Dienstag JL, Wei L-J, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Invest 2007;27:35-49.
29. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001;34:785-791.
30. Chan HLY, Heathcote JE, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med 2007;147:745-754.
31. Colonno R, Rose R, Pokornowski K, Baldick C, Eggers B, Yu D, et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients [abstr 781]. J Hepatol 2007;46(Suppl 1):S294.